688180 君實生物
按盤價 
48.000 +3.300 (+7.383%) | 2025/06 - 中期 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -6.747 | -19.689 | -27.454 | -27.404 | -10.469 |
| 總資產報酬率 ROA (%) | -3.675 | -11.579 | -19.107 | -20.243 | -7.576 |
| 投入資產回報率 ROIC (%) | -4.310 | -14.041 | -22.727 | -24.558 | -9.379 | 邊際利潤分析 |
| 銷售毛利率 (%) | 80.060 | 78.921 | 63.996 | 65.304 | 69.079 |
| 營業利潤率 (%) | -40.655 | -68.717 | -163.551 | -183.414 | -13.871 |
| 息稅前利潤/營業總收入 (%) | -39.342 | -69.686 | -170.296 | -189.759 | -14.004 |
| 淨利潤/營業總收入 (%) | -39.856 | -70.836 | -168.759 | -177.784 | -18.151 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 101.136 | 93.369 | 92.680 | 98.964 | 118.222 |
| 價值變動淨收益/利潤總額(%) | -7.261 | 5.247 | 3.018 | 1.913 | -11.050 |
| 營業外收支淨額/利潤總額(%) | 2.102 | 1.380 | 1.375 | 0.421 | 6.172 | 償債能力分析 |
| 流動比率 (X) | 1.612 | 1.718 | 2.285 | 4.086 | 2.920 |
| 速動比率 (X) | 1.424 | 1.483 | 2.064 | 3.746 | 2.678 |
| 資產負債率 (%) | 45.252 | 44.981 | 35.461 | 22.153 | 24.636 |
| 帶息債務/全部投入資本 (%) | 32.178 | 30.453 | 18.739 | 10.697 | 5.317 |
| 股東權益/帶息債務 (%) | 194.468 | 214.602 | 411.315 | 819.634 | 1,731.442 |
| 股東權益/負債合計 (%) | 120.609 | 120.838 | 177.791 | 340.888 | 292.256 |
| 利息保障倍數 (X) | -17.993 | 9,401.884 | 38.142 | 34.070 | -17.970 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 79.815 | 91.745 | 86.422 | 189.637 | 84.232 |
| 存貨周轉天數 (天) | 440.924 | 491.996 | 378.341 | 386.772 | 119.759 |
| 備註： | 即時報價更新時間為 05/09/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
